enrasentan has been researched along with aldosterone in 1 studies
| Studies (enrasentan) | Trials (enrasentan) | Recent Studies (post-2010) (enrasentan) | Studies (aldosterone) | Trials (aldosterone) | Recent Studies (post-2010) (aldosterone) |
|---|---|---|---|---|---|
| 32 | 2 | 0 | 25,333 | 1,517 | 4,169 |
| Protein | Taxonomy | enrasentan (IC50) | aldosterone (IC50) |
|---|---|---|---|
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0048 | |
| Mineralocorticoid receptor | Rattus norvegicus (Norway rat) | 0.043 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiyar, N; Anderson, KM; Barone, FC; Coatney, RW; Nelson, AH; Ohlstein, EH; Olzinski, AR; Willette, RN; Woods, T | 1 |
1 other study(ies) available for enrasentan and aldosterone
| Article | Year |
|---|---|
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Carboxylic Acids; Endothelin Receptor Antagonists; Heart Rate; Hypertension; Hypertrophy, Left Ventricular; Indans; Male; Myocardium; Protein Precursors; Rats; Rats, Inbred SHR; Survival Rate; Ventricular Remodeling | 2001 |